Title of Invention

NOVEL HERBAL COMPOSITION FOR THE TREATMENT OF GASTRIC ULCER

Abstract

The present invention relates to a novel herbal composition for the treatment of gastric ulcer, the said composition comprising 5 to 13 wt% of powdered plant parts of Asparagus racemosus; 5 to 12 wt% of powdered plant parts of Glycyrrhiza glabra; 8 to 14 wt% of powdered plant parts of Seaamum indicum; 7 to 14 wt% of powdered plant parts of Musa sapientum; 4 to 12 wt% of powdered plant parts of Trachyspermum roxburghianum; 6 to 12 wt% of powdered plant parts of Aloe barbadensis; 5 to 12 wt% of powdered plant parts of Evolvulus alsinoides; 6 to 13 wt% of powdered plant parts of Cyclea peltata; 9 to 14 wt% of powdered plant parts of Embelia ribes; 7 to 14 wt% of powdered plant parts of Coriandrum sativum; 8 to 13 wt% of powdered plant parts of Ferula asafoetida; optionally along with pharmaceutically acceptable excipients.

Full Text

Field of Invention The present invention relates to a novel herbal composition for the treatment of gastric ulcer. The present invention also relates to a method for the preparation of the said composition. The present invention further relates to a process for the treatment of gastric ulcer using the composition. Background and prior art to the Invention Various theories have been proposed with respect to a cause of ulcer in human. In particular, it has been elucidated that stress, taking of non-steroidal anti-inflammatory drugs for curing rheumatic diseases, and the like are closely related to ulcer formation, mainly due to relatively excess gastric or duodenal acid secretion. Accordingly it is important to suppress the acid secretion in order to prevent ulcer formation and to cure it. On the other hand it has been considered that Helicobacter pylori, which is a rod normally existing in stomach, generates ammonia due to its strong urease activity, thereby inducing ulcer. Since, it persistently lives within mucus and mucosa, it becomes the greatest cause for recurrence of ulcer. Accordingly, it has been considered that the recurrence of ulcer can be prevented, if this bacterium is sterilized. References may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol. 1, p 74-76, 155, published by Popular Prakashan Pvt. Ltd., Mumbai; K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 4, p 2505 published by Bishen Singh Mahendrapal Singh, Dehradun and P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 1, p 103 for the various medicinal properties of Aloe barbadensis. References may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol. 1, p 155 published by Popular Prakashan Pvt. Ltd., Mumbai; K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 4, p 2249 published by Bishen Singh Mahendrapal Singh, Dehradun; P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 1, p 218, and K. Narayana Iyer and M. Kolammal in Pharmacognosy of Ayurvedic Drugs (1963) Series 1, No. 6, p. 48 published by Department of Pharmacognosy, University of Kerala, Trivandrum for the various medicinal properties of Asperagus racemosus. References may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol. 1, p 582 published by Popular Prakashan Pvt. Ltd., Mumbai; K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 1, p. 728 published by Bishen Singh Mahendrapal Singh, Dehradun; P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 3, p 84, 86-87; The Wealth of India (1950-1980) Vol. 4, p. 152-153, published by Council of Scientific and Industrial Research; S.S. Handa in Indian Herbal Pharmacopeia (1998), p. 96, published by Regional Research Laboratory, Jammu and IDMA, Mumbai; Y.K. Sarin in Illustrated lanual of herbal drugs used in Ayurveda (1996), p. 116, and The Ayurvedic Pharmacopoeia of India, Vol. 1, p. 128, published by Ministry of Health and Family Welfare, India for the various medicinal properties of Glychyrrhiza glabra. References may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol. 1, p. 1127-28, published by Popular Prakashan Pvt. Ltd., Mumbai; K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 3, p 1858-89 published by Bishen Singh Mahendrapal Singh, Dehradun; P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 5, p 104, and The Wealth of India (1950-1980) Vol. 9, p. 290, published by Council of Scientific and Industrial Research for the various medicinal properties ofSeaamum indicum. References may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol. 1, p 531, published by Popular Prakashan Pvt. Ltd., Mumbai; P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 3, p. 11-12, and K. Narayana Iyer and M. Kolammal in Pharmacognosy of Ayurvedic Drugs (1963) Series 1, No. 6, p. 1, published by Department of Pharmacognosy, University of Kerala, Trivandrum for the various medicinal properties ofEvolvulus aisinodes. References may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol. 1, p822-825, published by Popular Prakashan Pvt. Ltd., Mumbai; K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 4, p. 2454, published by Bishen Singh Mahendrapal Singh, Dehradun, and P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 4, p 78 for the various medicinal properties of Musa sapientum. References may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol. 1, p 1028-1030, published by Popular Prakashan Pvt. Ltd., Mumbai; P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 3, p. 299, published by orient Longman, Chennai; The Wealth of India (1950-1980) Vol. 10, p. 271, published by Council of Scientific and Industrial Research; Y.K. Sarin in Illustrated lanual of herbal drugs used in Ayurveda (1996), p. 202, and The Ayurvedic Pharmacopoeia of India, Vol. 1, p. 3, published by Ministry of Health and Family Welfare, India for the various medicinal properties of Trachyaparmum roxburghic inum. References may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol. 1, p. 478, published by Popular Prakashan Pvt. Ltd., Mumbai; K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 2, p. 1479, published by Bishen Singh Mahendrapal Singh, Dehradun; P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 2, p. 368, published by orient Longman, Chennai; The Wealth of India (1950-1980) Vol. 3, p. 167, published by Council of Scientific and Industrial Research; Y.K. Sarin in Illustrated lanual of herbal drugs used in Ayurveda (1996), p. 290, and The Ayurvedic Pharmacopoeia of India, Vol. 1, p. 124, published by Ministry of Health and Family Welfare, India for the various medicinal properties of Embelia ribes. References may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol. 1, p. 381-82, published by Popular Prakashan Pvt. Ltd., Mumbai; K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 2, p. 1225, published by Bishen Singh Mahendrapal Singh, Dehradun; P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 2, p. 184, published by orient Longman, Chennai, and The Wealth of India (1950-1980) Vol. 3, p. 349, published by Council of Scientific and Industrial Research for the various medicinal properties ofCoriandrum sativum. Reference may be made to P.K. Warrier in Indian Medicinal Plants - A compendium of 500 species [1994-96] vol. 2, p-277, published by Orient Longman for the various medicinal properties of Cyclea peltata. References may be made to K. M. Nadkarni in Indian Materia Medica [1976] vol.1, p-537, published by popular Prakashan Pvt. Ltd., Mumbai; K.R. Kirtikar in Indian Medicinal Plants [1975], vol.2, p-1217, published by Bishan Singh Mahendrapal Singh, Dehradun; P.K. Warrier in Indian Medicinal Plants - A compendium of 500 species [1994-96] vol. 3, p-13, published by Orient Longman, Chennai; Y.K. Sarin in Illustrated manual of herbal drugs used in yurveda [1996], p-332, and The Ayurvedic Pharmacopoeia of India, p-50, published by Ministry of Helath and family welfare, India for the various medicibnal properties of Ferula asafetida. The composition of the present invention should not be treated as an obvious as it is a synergistic herbal composition not reported anywhere in the hitherto known prior art as well as none of the citations are able to provide all the advantages of the present invention. Objects of the Invention The main object of the present invention is thus to provide a novel synergistic herbal composition for the treatment of gastric ulcer. Yet another object of the present invention is to provide a process for the preparation of the composition. Still another object of the present invention is to provide a method for the treatment of gastric ulcer using the said composition. Summary of the Invention Accordingly, the present invention provides a novel herbal composition for the treatment of gastric ulcer, the said composition comprising 5 to 13 wt% of powdered plant parts of Asparagus racemosus; 5 to 12 wt% of powdered plant parts of Glycyrrhiza glabra; 8 to 14 wt% of powdered plant parts of Seaamum indicum;7 to 14 wt% of powdered plant parts of Musa sapientum; 4 to 12 wt% of powdered plant parts of Trachyspermum roxburghianum; 6 to 12 wt% of powdered plant parts of Aloe barbadensis; 5 to 12 wt% of powdered plant parts of Evolvulus alsinoides; 6 to 13 wt% of powdered plant parts of Cyclea peltata; 9 to 14 wt% of powdered plant parts of Embetia ribes; 7 to 14 wt% of powdered plant parts of Coriandrum sativum; 8 to 13 wt% of powdered plant parts of Ferula asafoetida; optionally along with pharmaceutically acceptable excipients. Detailed Description of the Invention In accordance with the first embodiment of the present invention, there is provided a synergistic herbal composition for the treatment of gastric ulcer, said composition essentially comprising of powdered plant parts of Asparagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum and Trachyaparmum roxburghicinum and optionally, powdered plant parts of Cyclea peltate, Embelia ribes, Coriandrum sativum, Ferula asafoetida, Aloe barbadensis and Evolvulus aisinodes along with one or more pharmaceutically acceptable additives/carriers. In an embodiment of the present invention, the composition comprises powdered plant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum and Trachyaparmum roxburghicinum in equal proportions, optionally along with one or more pharmaceutically acceptable additives/carriers. This composition is hereafter referred to as HF3. In another embodiment of the present invention, the composition comprises powdered plant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum, Evolvulus aisinodes and Ferula asafoetida in equal proportions, optionally along with one or more pharmaceutically acceptable additives/carriers. This composition is hereafter referred to as HF4. In yet another embodiment of the present invention, the composition comprises powdered plant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum, Evolvulus aisinodes, Ferula asqfoelida, Coriandrum sativum, Cyclea peltate and Aloe barbadensis in equal proportions, optionally along with one or more pharmaceutically acceptable additives/carriers. This composition is hereafter referred to as HF5. In still another embodiment of the present invention, the composition comprises 5-13 wt. % of powdered plant parts of Asperagus racemosus, 5-12 wt. % of powdered plant parts of Glycyrrhiza glabra, 8-14 wt. % of powdered plant parts of Seaamum indicum, 7-14 wt. % of powdered plant parts of Musa sapientum, 4-12 wt. % of powdered plant parts of Trachyaparmum roxburghicinum, 6-12 wt. % of powdered plant parts of Aloe barbadensis, 5-12 wt. % of powdered plant parts of Evolvulus aisinodes, 6-13 wt. % of powdered plant parts of Cyclea peltate, 9-14 wt. % of powdered plant parts of Embelia ribes, 7-14 wt. % of powdered plant parts of Coriandrum sativum and 8-13 wt. % of plant parts of Ferula asafoetida, optionally along with one or more pharmaceutically acceptable additives/carriers. This composition is hereafter referred toasHF2. In one more embodiment of the present invention, the plant part of Trachyaparmum roxburghicinum, Embelia ribes and Coriandrum sativum is fruit. In one another embodiment of the present invention, the plant part of Cyclea peltate and Glycyrrhiza glabra is root. In a further embodiment of the present invention, the plant part of Aloe barbadensis is elio. In a furthermore embodiment of the present invention, the plant part of Asperagus racemosus is tuber. In an embodiment of the present invention, the plant part of Seaamum indicum is seed. In another embodiment of the present invention, the plant part of Musa sapientum is unripe fruit. In yet another embodiment of the present invention, the plant part of Ferula asafoetida is resin. In accordance with the another embodiment of the present invention, there is provided a synergistic herbal composition for the treatment of gastric ulcer, said composition comprising equal proportions of 10 powdered plant parts selected from the group comprising of powdered plant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum, Cyclea peltate, Embelia ribes, Coriandrum sativum, Ferula asafoetida, Aloe barbadensis and Evolvulus aisinodes, optionally along with one or more pharmaceutically acceptable additives/carriers. In an embodiment of the present invention, said composition comprises equal proportions of powdered plant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum, Cyclea peltate, Embelia ribes, Coriandrum sativum, Ferula asafoetida and Aloe barbadensis, optionally along with one or more pharmaceutically acceptable additives/carriers. In another embodiment of the present invention, said composition comprises equal proportions of powdered plant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum, Cyclea peltate, Embelia ribes, Coriandrum sativum, Ferula asafoetida and Evolvulus aisinodes, optionally along with one or more pharmaceutically acceptable additives/carriers. In yet another embodiment of the present invention, said composition comprises equal proportions of powdered plant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum, Cyclea peltate, Embelia ribes, Coriandrum sativum, Aloe barbadensis and Evolvulus aisinodes, optionally along with one or more pharmaceutically acceptable additives/carriers. In still another embodiment of the present invention, said composition comprises equal proportions of powdered plant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum, Cyclea peltate, Embelia ribes, Ferula asafoetida, Aloe barbadensis and Evolvulus aisinodes, optionally along with one or more pharmaceutically acceptable additives/carriers. In one more embodiment of the present invention, said composition comprises equal proportions of powdered plant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum, Cyclea peltate, Coriandrum sativum, Ferula asafoetida, Aloe barbadensis and Evolvulus aisinodes, optionally along with one or more pharmaceutically acceptable additives/carriers. In one another embodiment of the present invention, said composition comprises equal proportions of powdered plant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum, Embelia ribes, Coriandrum sativum, Ferula asafoetida, Aloe barbadensis and Evolvulus aisinodes, optionally along with one or more pharmaceutically acceptable additives/carriers. In a further embodiment of the present invention, said composition comprises equal proportions of powdered plant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Cyclea peltate, Embelia ribes, Coriandrum sativum, Ferula asafoetida, Aloe barbadensis and Evolvulus aisinodes, optionally along with one or more pharmaceutically acceptable additives/carriers. In a further more embodiment of the present invention, said composition comprises equal proportions of powdered plant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Trachyaparmum roxburghicinum, Cyclea peltate, Embelia ribes, Coriandrum sativum, Ferula asafoetida, Aloe barbadensis and Evolvulus aisinodes, optionally along with one or more pharmaceutically acceptable additives/carriers, In an embodiment of the present invention, said composition comprises equal proportions of powdered plant parts of Asperagus racemosus, Glycyrrhiza glabra, Musa sapientum, Trachyaparmum roxburghicinum, Cyclea peltate, Embelia ribes, Coriandrum sativum, Ferula asafoetida, Aloe barbadensis and Evolvulus aisinodes, optionally along with one or more pharmaceutically acceptable additives/carriers. In another embodiment of the present invention, said composition comprises equal proportions of powdered plant parts of Asperagus racemosus, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum, Cyclea peltate, Embelia ribes, Coriandrum sativum, Ferula asafoetida, Aloe barbadensis and Evolvulus aisinodes, optionally along with one or more pharmaceutically acceptable additives/carriers. In yet another embodiment of the present invention, said composition comprises equal proportions of powdered plant parts of Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum, Cyclea peltate, Embelia ribes, Coriandrum sativum, Ferula asafoetida, Aloe barbadensis and Evolvulus aisinodes, optionally along with one or more pharmaceutically acceptable additives/carriers. In accordance with the second embodiment of the present invention, there is provided a process for the preparation of the novel synergistic herbal composition for the treatment of gastric ulcer, said process comprising the steps of powdering plant parts essentially selected from Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum and Trachyaparmum roxburghicinum and optionally, selected from Cycle a peltate, Embelia ribes, Coriandrum sativum Ferula asafoetida, Aloe barbadensis and Evolvulus aisinodes, mixing the aforesaid powdered plant parts to obtain a mixture and optionally adding one or more pharmaceutical ly acceptable additives/carriers to the above mixture. In an embodiment of the present invention, said process comprises the steps of powdering plant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum and Trachyaparmum roxburghicinum, mixing the aforesaid plant parts in equal proportions to obtain a mixture and optionally adding one or more pharmaceutically acceptable additives/carriers to the above mixture. In another embodiment of the present invention, said process comprises the steps of powdering plant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum, Evolvulus aisinodes and Ferula asafoetida, mixing the aforesaid plant parts in equal proportions to obtain a mixture and optionally adding one or more pharmaceutically acceptable additives/carriers to the above mixture. In yet another embodiment of the present invention, said process comprises steps of powdering plant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum, Evolvulus aisinodes, Ferula asafoetida, Coriandrum sativum, Cyclea peltate and Aloe barbadensis, mixing the aforesaid plant parts in equal proportions to obtain a mixture and optionally adding one or more pharmaceutically acceptable additives/carriers to the above mixture. In still another embodiment of the present invention, said process comprises the steps of powdering and mixing 5-13 wt. % of plant parts of Asperagus racemosus, 5-12 wt. % of plant parts of Glycyrrhiza glabra, 8-14 wt. % of plant parts of Seaamum indicum, 7-14 wt. % of plant parts of Musa sapientum, 4-12 wt. % of plant parts of Trachyaparmum roxburghicinum, 6-12 wt. % of plant parts of Aloe barbadensis, 5-12 wt. % of plant parts of Evolvulus aisinodes, 6-13 wt. % of plant parts of Cyclea peltate 9-14 wt. % of plant parts of Embelia ribes, 7-14 wt. % of plant parts of Coriandrum sativum and 8-13 wt. % of plant parts of Ferula asafoetida to obtain a mixture and optionally adding one or more pharmaceutically acceptable additives/carriers to the above mixture. In one more embodiment of the present invention, the plant part of Trachyaparmum roxburghicinum, Embelia ribes and Coriandrum sativum is fruit. In one another embodiment of the present invention, the plant part of Cyclea peltate and Glycyrrhiza glabra is root. In a further embodiment of the present invention, the plant part of Aloe barbadensis is elio. In a furthermore embodiment of the present invention, the plant part of Asperagus racemosus is tuber. In an embodiment of the present invention, the plant part of Seaamum indicum is seed. In another embodiment of the present invention, the plant part of Musa sapientum is unripe fruit. In yet another embodiment of the present invention, the plant part of Ferula asqfoetida is resin. In accordance with another object of the present invention, there is provided a method of treating gastric ulcer in a subject, said method comprising administering an effective amount of the synergistic herbal composition essentially comprising of powdered plant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum and Trachyaparmum roxburghicinum and optionally, powdered plant parts of Cyclea peltate, Embelia ribes, Coriandrum sativum Ferula asqfoetida. Aloe barbadensis and Evolvulus aisinodes along with one or more pharmaceutically acceptable additives/carriers. In an embodiment of the present invention, said method comprises administering an effective amount of the synergistic herbal composition comprising of powdered plant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum and Trachyaparmum roxburghicinum in equal proportions, optionally along with one or more pharmaceutically acceptable additives/carriers. In another embodiment of the present invention, said method comprises administering an effective amount of the synergistic herbal composition comprising of powdered plant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum, Evolvulus aisinodes and Ferula usafoetida in equal proportions, optionally along with one or more pharmaceutically acceptable additives/carriers. In yet another embodiment of the present invention, said method comprises administering an effective amount of the synergistic herbal composition comprising of powdered plant parts of Asperagus racemosus, Glycyrrhiza glabra, Seaamum indicum, Musa sapientum, Trachyaparmum roxburghicinum, Evolvulus aisinodes, Ferula asafoetida, Coriandrum sativum, Cyclea peltate and Aloe barbadensis in equal proportions, optionally along with one or more pharmaceutically acceptable additives/carriers. In still another embodiment of the present invention, said method comprises administering an effective amount of the synergistic herbal composition comprising 5-13 wt. % of powdered plant parts of Asperagus racemosus, 5-12 wt. % of powdered plant parts of Glycyrrhiza glabra, 8-14 wt. % of powdered plant parts of Seaamum indicum, 7-14 wt. % of powdered plant parts of Musa sapientum, 4-12 wt. % of powdered plant parts of Trachyaparmum roxburghicinum, 6-12 wt. % of powdered plant parts of Aloe barbadensis, 5-12 wt. % of powdered plant parts of Evolvulus aisinodes, 6-13 wt. % of powdered plant parts of Cyclea peltate 9-14 wt. % of powdered plant parts of Embelia ribes, 7-14 wt. % of powdered plant parts of Coriandrum sativum and 8-13 wt. % of plant parts of Ferula asafoetidain equal proportions, optionally along with one or more pharmaceutically acceptable additives/carriers. In one more embodiment of the present invention, the subject is a mammal including human. In one another embodiment of the present invention, the effective dosage of the composition per day is in the range of 5 to 15g. In a further embodiment of the present invention, the composition can be in the form of tablets, capsules, syrup and any other conventional forms. In a furthermore embodiment of the present invention, the composition is administered orally, intra-muscularly, and by any other conventional methods. In an embodiment of the present invention, the composition may be used for therapeutic as well as prophylactic treatment of gastric ulcer. In another embodiment of the present invention, the subject may be administered a bolus dose or a multiple dose. In yet another embodiment of the present invention, wherein the composition HF2 showed more than 62% protection against cold restraint ulcer model. In still another embodiment of the present invention, wherein the composition HF2 showed more than 30 % protection against aspirin induced ulcer model. In one more embodiment of the present invention, wherein the composition HF2 reduced the length of hemorrhagic bands to 22.67 ± 4.69 (mm ± SE) against alcohol induced gastric ulcer. In one another embodiment of the present invention, wherein the composition HF2 has protection index greater than 80 against pyloric ligation induced ulcer. Brief Description of the Tables In the tables accompanying the specification, Table 1 represents the effect of the herbal composition HF2 prepared in accordance with one of the embodiments of the present invention and a standard drug "Omeprazole" against Cold Restraint (at 4' C temp, for 2 hrs.) induced Ulcer (CRU). Table 2 represents the effect of the herbal composition HF2 prepared in accordance with one of the embodiments of the present invention and the standard drug "Omeprazole" against aspirin induced gastric ulcer. Table 3 represents the effect of the herbal composition HF2 prepared in accordance with one of the embodiments of the present invention and the standard drug "Omeprazole" against alcohol induced gastric ulcer in rats. Table 4 represents the effect of the herbal composition HF2 prepared in accordance with one of the embodiments of the present invention and the standard drug "Omeprazole" against Histamine induced ulcer model. Table 5 represents the effect of the herbal composition HF2 prepared in accordance with one of the embodiments of the present invention and a standard drug "Omeprazole" against Pyrolic ligation induced ulcer model. Table 6 gives the composition of the Herbal composition HF2 prepared in accordance with one of the embodiments of the present invention. Table 7 provides the antigastric ulcer activity of herbal compositions HF3, HF4 and HF5 prepared in accordance with the embodiments of the present invention against cold restrained ulcer model, pyloric ligation ulcer model and alcohol induced ulcer model. Table 8 provides the results of the study conducted to evaluate the synergistic effect of the composition HF2. Table 9 gives the composition of the Herbal compositions HF3, HF4 and HF5. The invention is further described with respect to the following experiments which are given by way of illustration and therefore should not be construed to limit the scope of the invention in any manner. Experimental protocol: Invivo experiments: The Applicants have carried out several experiments under different induced ulcer conditions and the effect of the herbal composition were studied and are tabulated herebelow. The effect of the herbal composition has been compared with respect to a known anti-ulcer drug "Omeprazole". EXPERIMENT 1: EFFECT ON COLD RESTRAINT ULCERS (CRU) MODEL METHOD: Adult rats of either sex, weighing 150-175 Gms were fasted for 24 hours with free access to water. The test drugs were administered 45 minutes before immobilizing the animals. The rats were immobilized in the restraint cage at 4°C in BOD incubator for 2 hrs and were sacrificed immediately after the restraint period. (According to the method of Senay and Levine 1967). The abdomen was cut opened; stomach was taken out and incised along the greater curvature to observe the gastric lesions with the help of Magnascope (5X magnification). The following arbitrary scoring system was used to grade the severity and intensity of the lesions. 1. Shedding of epithelium = 10 2. Petechial and frank hemorrhages = 20 3. One or two ulcers^ 30 4. More than two ulcers = 40 5. Perforated ulcers = 50 The presence of any of these lesions was considered as a positive ulcerogenic response which has been shown as percentage of rats showing gastric lesions. The severity of ulcers is expressed in terms of ulcer index, which is the mean score of gastric lesions of all the rats in a group which is defined as: Ulcer Index (U.I.) = Us + Up x 10'1 Where Us = Mean severity of ulcer score and Up - Percentage of animals with Ulcer incidences The percentage protection is calculated as follows: Percentage protection = (C-T/C) x 100. Wherein C= Number of animals showing ulcer response in control group and T= Number of animals showing ulcer response in test group. The effect of the Herbal Composition of the present invention hereafter referred to as "HF2" against Cold Restraint Ulcer Model (CRU) is given in Table 1. The effect of the standard drug "Omeprazole" is also given in Table 1. TABLE 1: THE EFFECT OF THE HERBAL COMPOSITION "HF2" AND THE STANDARD DRUG "OMEPRAZOLE" AGAINST COLD RESTRAINT ULCER MODEL (CRU). (Table Removed) INFERENCE: Omeprazole showed 54.03 % protection where as the composition HF2 showed 62.90%, protection against gastric ulcer. Thus it is clear that the composition HF2 provides significantly better protection against cold restraint ulcer model as compared to Omeprazole. EXPERIMENT 2: EFFECT ON ASPIRIN INDUCED GASTRIC ULCER MODEL METHOD: Gastric ulceration was induced by aspirin according to the method of Djahanguiri (1969). Aspirin (150 mg/Kg.) was administered per orally as a suspension in gum-acacia and Ihe animal was sacrificed 5 hr. after the aspirin treatment and the ulcer index with protection index were calculated. The results of the experiment is tabulated in Table 2. The effect of the herbal composition HF2 and the standard drug "Omeprazole" against aspirin induced gastric ulcer is given in Table 2. TABLE 2: THE EFFECT OF THE HERBAL COMPOSITION "HF2" AND THE STANDARD DRUG "OMEPRAZOLE" AGAINST ASPIRIN INDUCED GASTRIC ULCER Comp ounds and Doses (Table Removed) INFERENCE: Both Omeprazole and the composition HF2 showed equal protection (39.41 % protection) against aspirin induced ulcer model. EXPERIMENT 3: EFFECT ON ALCOHOL INDUCED GASTRIC ULCERS IN RATS METHOD: Adult rats of either sex were taken; weighing 150 -175 grams were fasted for 24 hours with free access to water. The test drugs were administered (p.o.) 45 minutes before albohol administration. 1 ml of chilled absolute alcohol was administered (p.o.) to the rats (According to Wittetal)3. Immediately after 1 hour, the animals were anesthetized, abdomen was cut opened stomach was taken out and incised along the greater curvature to observe the gastric lesions. The ulcers are examined under the 5X magnification with the help of magnascope. Absolute ethanol lesions appears as blackish lesions grouped in patches of varying size, usually parallel to the major axis of the stomach. The lengths of the lesions are measured and summated to give a total lesion score, then calculated and expressed in percentage. The effect of the herbal composition "HF2" and the standard drug "Omeprazole" against alcohol induced gastric ulcer in rats is given in Table 3. TABLE 3: THE EFFECT OF THE HERBAL COMPOSITION "HF2" AND THE STANDARD DRUG "OMEPRAZOLE" AGAINST ALCOHOL INDUCED GASTRIC ULCER IN RATS Length of hemorrhagic bands (mm ± SE) Compound_ 73.5 ±1.5 22.67 ± 4.69 Ethanol control "W2 (100 mg/kgrp.o.) + Ethanol 56.0 + 9.12 Omeprazole (100 mg/kg, p.o.) + Ethanol INFERENCE: The composition of the present invention showed significant protection against this model also. The protection provided by the composition of the present invention is better than Omeprazole. EXPERIMENT 4: EFFECT ON fflSTAMINE INDUCED ULCER MODEL METHOD: Animals were fasted for 24 hours with access to water. The drug was given orally 1 hour prior to the histamine administration. Histamine was administered in a dose of 0.25 mg/Kg, i.m. at 30 minutes interval -for 7 times and it induced 100 % duodenal ulceration in guinea pig (According to the method of Watt and Eagleton 1964)4. The animals were sacrificed after half an hour of last injection under ether anesthesia. The stomach along with duodenum was removed washed thoroughly and examined for the lesions and ulcer index with protection index was calculated. The results of the experiment are tabulated in Table 4. The effect of the herbal composition "HF2" and the standard drug "Omeprazole" against Histamine induced ulcer model is given in Table 4. EXPERIMENT 5: EFFECT ON PYLORIC LIGATION INDUCED ULCER MODEL METHOD: Animals were fasted for 24 hours in the raised mesh bottom cages to prevent coprophagia and were allowed free access to water. The control group of rats was feed with the vehicle and the experimental groups with their respective drugs 45 minutes prior to the ligation. The animal was anesthetized, abdomen was cut opened under xiphoid process, and the pyloric portion of the stomach was slightly lifted and ligated avoiding any damage to the adjacent blood vessels (According to the method of Shay et al. 1945). The animals were stitched and kept for 4 hours with free access to water. After 4 hours the animals were sacrificed under ether anesthesia and the stomach was dissected out incised along the greater curvature. The stomach was washed thoroughly and the ulcer index was scored as per in other ulcer models. The results of the experiment are tabulated in Table 5. TABLE 4: THE EFFECT OF THE HERBAL COMPOSITION "HF2" AND THE STANDARD DRUG "OMEPRAZOLE" AGAINST fflSTAMINE INDUCED ULCER MODEL (Table Removed) INFERENCE: In this model, Omeprazole showed 70.79% protection whereas the composition HF2 showed 68.3% protection. In comparison, the composition HF2 provides more or less equal protection. The effect of the herbal composition "HF2" and the standard drug "Omeprazole" against Pyloric ligation induced ulcer model is given in Table 5. TABLE 5: EFFECT OF OMEPRAZOLE AND THE HERBAL COMPOSITION HF2 AGAINST PYLORIC LIGATION INDUCED ULCER (Table Removed) INFERENCE: The composition of the present invention showed better protection than Omeprazole in the pyloric ligation induced ulcer model. EXPERIMENTS EFFECT OF THE PRESENT COMPOSITION ON ACETYLCHOLINE AND HISTAMINE INDUCED CONTRACTION OF GUINEA-PIG ILEUM METHOD: A piece of 2 - 3 cm of the terminal ileum of a freshly killed Guinea pig was suspended in an organ bath containing Tyrode solution at 34° C and bubbled with fresh air. Contraction was induced by submaximal contraction of acetylcholine chloride (1 [ig/mL) and Histamine (1 ng/mL) and it was recorded on a kymograph (According to the method of Patnaikl992). The composition HF2 (up to 250 ng / mL) did not exert any significant influence on isolated tissue preparation for anticholinergic (acetylcholine-induced contraction of Guinea-pig ileum) and Fk-anti-histaminic (Histamine induced contraction of Guinea-pig ileum) activity. EXPERIMENT 7: HERBS AND PREPARATION OF THE COMPOSITION For the purpose of conducting animal experiment all the herbs are washed dried and pulverised. All the herbs are taken in the proportion as shown in Table 6. The whole mixture is blended well and used for administering. The components and their proportions of the standard herbal composition according to one embodiment of the present invention are listed in Table 6. The part of the herb which is used is also mentioned. The placebo preparation is designed to taste, smell and look like an Ayurvedic herbal composition. TABLE 6: THE COMPOSITION OF THE HERBAL COMPOSITION HF2 (Table Removed) TABLE 7: ANTIGASTRIC ULCER ACTIVITY OF THE HERBAL Formulation COMPOSITIONS HF3, HF4 AND HF5 (Table Removed) In order to conduct a study on the synergistic effect, the herbal composition HF2 was taken and each component was removed and the effect of the resultant composition against cold restrained gastric ulcer model was studied. The results of the experiment thus conducted is tabulated in Table 8. It was concluded from the above experiments that the batch prepared by the removal of Emblica ribes has shown very good protection. TABLE 8: RESULTS OF THE SYNERGISTIC EFFECT STUDY (Table Removed) To TABLE 9: COMPOSITION OF THE HERBAL COMPOSITIONS HF3, HF4 HF3 1. Asperagus racemosus 2. Glycyrrhiza glabra 3. Seaamum indicum 4. Musa sapientum and 5. Trachyaparmum roxburghicinum All in equal proportions AND HF5 HF4 1. Asperagus racemosus 2. Glycyrrhiza glabra 3. Seaamum indicum 4. Musa sapientum 5. Trachyaparmum roxburghicinum 6. Evolvulus aisinodes and 7. Ferula asafoetida All in equal proportions HF5 1. Asperagus racemosus 2. Glycyrrhiza glabra 3. Seaamum indicum 4. Musa sapientum 5. Trachyaparmum roxburghicinum 6. Evolvulus aisinodes 1. Ferula asafoetida 8. Coriandrum sativum 9. Cycleapeltate and \O.Aloe barbadensis All in equal proportions We claim: 1. A novel herbal composition for the treatment of gastric ulcer, the said composition comprising: [a] 5 to 13 wt% of powdered plant parts of Asparagus racemosus; [b] 5 to 12 wt% of powdered plant parts of Glycyrrhiza glabra; [c] 8 to 14 wt% of powdered plant parts of Seaamum indicum; [d] 7 to 14 wt% of powdered plant parts of Musa sapientum; [e] 4 to 12 wt% of powdered plant parts of Trachyspermum roxburghianum; [fj 6 to 12 wt% of powdered plant parts of Aloe barbadensis; [g] 5 to 12 wt% of powdered plant parts of Evolvulus alsinoides; [h] 6 to 13 wt% of powdered plant parts of Cyclea peltata; [i] 9 to 14 wt% of powdered plant parts of Embelia ribes; [j] 7 to 14 wt% of powdered plant parts of Coriandrum sativum; [k] 8 to 13 wt% of powdered plant parts of Ferula asafoetida; [1] optionally along with pharmaceutically acceptable excipients. 2. A composition as claimed in claim 1, wherein the plant part of Trachyspermum roxburghianum, Embelia ribes, Coriandrum sativum is fruit. 3. A composition as claimed in claim 1, wherein the plant part of Cyclea peltata and Glycyrrhiza glabra is root. 4. A composition as claimed in claim 1, wherein the paint part of Aloe barbadensis is elio. 5. A composition as claimed in claim 1, wherein the plant part of Seaamum indicum is seed. 6. A composition as claimed in claim 1, wherein the plant part of Asparagus racemosus is tuber. 7. A composition as claimed in claim 1, wherein the plant part of Musa sapientum is unripe fruit. 8. A composition as claimed in claim 1, wherein the plant part of Ferula asafoetida is resin. 9. A novel herbal composition for the treatment of gastric ulcer substantially as herein described with reference to the foregoing examples.

Documents:

1340-DEL-2003-Abstract-(10-06-2008).pdf

1340-del-2003-abstract.pdf

1340-DEL-2003-Claims-(10-06-2008).pdf

1340-del-2003-claims.pdf

1340-DEL-2003-Correspondence-Others-(10-06-2008).pdf

1340-DEL-2003-Correspondence-Others-(23-06-2008).pdf

1340-del-2003-correspondence-others.pdf

1340-del-2003-description (complete)-10-06-2008.pdf

1340-del-2003-description (complete).pdf

1340-DEL-2003-Form-1-(10-06-2008).pdf

1340-DEL-2003-Form-1-(23-06-2008).pdf

1340-del-2003-form-1.pdf

1340-del-2003-form-18.pdf

1340-DEL-2003-Form-2-(10-06-2008).pdf

1340-del-2003-form-2.pdf

1340-DEL-2003-Form-26-(10-06-2008).pdf

1340-DEL-2003-Form-3-(10-06-2008).pdf

1340-del-2003-form-3.pdf

1340-DEL-2003-Petition-137-(10-06-2008).pdf

1340-DEL-2003-Petition-138-(10-06-2008).pdf

1340-DEL-2003-Petition-138-(23-06-2008).pdf